Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Prolect (0704-0188), Washington, DC 20503
AGENCY USE ONLY (Leave blank)2. REPORT DATE
April 2001
REPORT TYPE AND DATES COVEREDAnnual (1 Apr 00 -31 Mar 01)
TITLE AND SUBTITLEA Novel RNA Virus System for Selective Killing of Breast Cancer Cells
AUTHOR(S)Griffith D. Parks, Ph.D.
FUNDING NUMBERS
DAMD17-00-1-0488
PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)Wake Forest University School of Medicine Winston-Salem, North Carolina 27157 E-Mail: gparks@wfubmc.edu The goal of the proposed work is to develop novel methods based on recombinant SV5 (rSV5) for targeting and killing predetermined populations of tumor cells. During the previous funding period, we have accomplished our proposed phases of the approved tasks. First, we have constructed new chimeric proteins composed of SV5 glycoproteins linked to a single chain antibody (sFv) specific for human HER-2. We have developed an assay to test functional interactions between these chimeras and HER-2, and have used flow cytometry to identify optimal forms of sFv for cell surface expression (Task 1). We are currently testing this chimera for expression in rSV5-infected cells. Second, we have generated human breast cancer cell lines which express the tet-repressor protein (Task 2). These stable cell lines are important as they will serve as the inducible target cells which will be induced to express varying levels of HER-2 to test the specificity of our rSV5 targeting model. Thus, our progress over the last year has resulted in identifying two important components for our research plan: a candidate anti-HER-2 sFv for inserting into rSV5 genome and cell lines which will be the targets for testing the specificity of targeted infection and killing. Introduction.
PERFORMING ORGANIZATION REPORT NUMBER
SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES)U
SUBJECT TERMSViruses and virus-based vectors represent a powerful tool for the delivery of recombinant molecules to cells. However, a major drawback to current systems has been the inability to target and limit an infection by a recombinant virus to predetermined cell types or tissue. The goal of the proposed work is to develop a novel method based on recombinant SV5 (rSV5) for targeting and killing predetermined population of tumor cells. The hypothesis to be tested is that the cell-type specificity of an SV5 infection can be pre-determined by incorporating the appropriate foreign...